Ixico Plc · LSE:IXI
Ixico — Investor Day (April 2026)
20 slides from Ixico's investor day presentation, Apr 1, 2026
Slide 1: IXICO plc – Placing: Scaling technology to increase shareholder value
ixico.com IXICO plc Placing – Scaling technology to increase shareholder value STRICTLY © IXICO PLC PRIVATE 2026 & CONFIDENTIAL | ALL RIGHTS RESERVED © IXICO PLC 2026
Slide 2: Non-regulated disclaimer 1/2
Non-regulated disclaimer 1/2 This presentation has been prepared by IXICO plc ("IXICO" or the "Company") and is for information purposes only. This presentation has been produced solely to provide a preliminary basis for potential investors to consider whether to pursue an acquisition of securities
Slide 3: Non-regulated disclaimer 2/2
Non-regulated disclaimer 2/2 correctness of the information or opinions contained herein and each recipient of this presentation must make their own investigation and assessment of the matters contained herein. Any person who is in doubt about the Placing should consult with an independent financial
Slide 4: IXICO – Established AI-driven neuroscience expertise
IXICO – Established AI-driven neuroscience expertise Seeking £10m Placing >80 employees (‘IXICANs’ - 27% PhDs) A leading iCRO focussed 28 current studies with… exclusively on CNS 17 leading global pharma, biotech & diagnostics Co’s 20 years of neuroscience expertise delivering gold standard clinical
Slide 5: An AI-enabled platform for precision medicine
an AI-enabled platform for precision medicine Standardised capture, analysis and reporting of regulatory Hospital compliant clinical data Pharma Readers’ platform Pharma, Pharma /Biotech, Biotech MR images Diagnostic sponsor Co. Drug and diagnostic PET images development Clinical development Upload
Slide 6: IXICO – Business model
IXICO– Business model Delivering insights to Biopharma enabling ‘make or break’ decisions Alzheimer's Disease IXICO AI PLATFORM Imaging biomarkers Huntington's Disease Drug safety Multiple Sclerosis Patient Parkinson's Trial management Disease eligibility Other: Demyelinating IXICO EXPERTISE Drug Di
Slide 7: FY25 Traction - 2024 Fund Raise
FY25 Traction - 2024 Fund Raise ‘Innovate Lead Scale’ to accelerate revenue growth RAG FY25 investments & outcomes New AD/PD product offerings INNOVATE Deployment of next gen IXI Product differentiation TA diversification Technology expansion Disease diversification Novel IXI applications & revenues
Slide 8: Growth Opportunity - 2026 Fund Raise
Growth Opportunity - 2026 Fund Raise Leveraging the IXITM PREVIOUS Accelerated iCRO strategy execution technology to create PLACING true company value (2024) NEW Expanded technology strategy execution TA expansion & innovation Geographic PLACING footprint Pipeline/revenue (2026) recovery iCRO growth
Slide 9: Growth Opportunity - AI – Automation - Data
Growth Opportunity - AI – Automation - Data AI Sentiment & Disruption – Life Science Sector What emerging trends do you think will have the most significant impact on your industry in the next 3–5 years? (Select up to your top 3) Automation and AI 68 Funding landscape 48 Data analytics and big data
Slide 10: IXICO - positioning for future growth
IXICO - positioning for future growth Scale across the wider neurology precision medicine landscape CLINICAL TRIAL MANAGEMENT CLINICAL DECISION SUPPORT RADIOLOGY* *Examples of (Diagnostics) CLINICAL DATA* RADIOLOGY* market participants (Hardware) IMAGING CRO BLOOD (Diagnostics) CRO* CUSTOMER Biophar
Slide 11: Future Growth – new routes to market
Future Growth – new routes to market Leveraging clinical trial management ecosystem partners for new revenue streams using IXITM CLINICAL DATA BioPharma enterprise license £ CRO - fee for service £ CRO enterprise license £ Subscription £ 11
Slide 12: XI partnership agreement
XI partnership agreement ONE-STOP-SHOP FOR CUSTOMERS BioPharma Single sign on | Standardised protocols | Integrated platforms | Low friction & familiarity (existing systems) Global multi $bn EDC platform serving >35k+ trials across 140 countries EDC partner IXICO BENEFIT Query handling Image upload
Slide 13: Addressable Growth Opportunity
Addressable Growth Opportunity The TechBio opportunity addressable market. Unlocking 2027 2028 2029 2030 … the platform and removing barriers CDSS** ($700-950m) • IXI as a medical device • Imaging hardware integration • Multimodal analyses (e.g. BBBM) TECHBIO ($300-450m) 2021 2022 2023 2024 2025 202
Slide 14: Growth Opportunity – From bespoke services to scalable tech
Growth Opportunity – From bespoke services to scalable tech Revenue Value (x Growth revenues) current iCRO New algorithms & tools Combined imaging & BBB =15% 1-3x Advancing technology for use within IXICO to expand service New CNS disease areas offering new Platform integration TechBio Platform auto
Slide 15: Use of proceeds
Use of proceeds Placing: £10m Retail offer: Up to £0.5m Timing: March 2026 VCT/EIS qualifying: Application for EIS Advance Assurance submitted via Philip Hare & Associates in respect of the £3m headroom under current EIS legislation. The balance of the raise that is seeking to be treated as VCT/EIS
Slide 16: A team to deliver growth
A team to deliver growth Board Members Deepened expertise focused on CEO Mark Warne Dipti Amin Kate Rogers global footprint expansion and revenue growth (Chair) (NED) (NED) Bram Goorden* Existing roles Expanded roles New roles HR Legal QA/RA CFO / COO CSO / CMO CTO CBO CCO Hannah Anna-Maria John Gre
Slide 17: Future Growth - Leveraging technology to create value
Future Growth - Leveraging technology to create value PREVIOUS Accelerated iCRO strategy execution PLACING (2024) NEW Expanded technology strategy execution TA expansion & innovation Geographic PLACING footprint Pipeline/revenue (2026) recovery iCRO growth TechBio iCRO Revenue (£m) Technology dev &
Slide 18: Investment summary
Investment summary Scale across the wider neurology precision medicine landscape Established iCRO for 20 years – a market leader in CNS imaging, high scarcity value as a leading neuroimaging platform with cutting edge technology Back on a clear growth trajectory – Innovate Lead Scale strategy result
Slide 19: Investment case – clear transformation strategy & execution
Investment case – clear transformation strategy & execution Financial VALUE CREATION Strong revenue & OB growth performance 1. Maximise iCRO opportunity 2. Revenue expansion through technology Scientific Trusted expertise with book of loyal repeat business clients track record Technology Full potent
Slide 20: IXICO plc contact details
Investor Relations: james.chandler@ixico.com IXICO plc 4th Floor, Griffin Court 15 Long Lane London EC1A 9PN STRICTLY © IXICO PLC PRIVATE 2026 & CONFIDENTIAL | ALL RIGHTS RESERVED © IXICO PLC 2026